Generic Medicine Info
Acute narrow-angle glaucoma; myasthenia gravis; respiratory depression; coma; acute pulmonary insufficiency; sleep apnoea syndrome; severe hepatic impairment. Chronic psychosis. Porphyria. Should not be used alone to treat depression or anxiety associated with depression.
Special Precautions
Chronic pulmonary insufficiency, muscle weakness, organic brain changes, impaired liver or kidney function, or in patients with history of alcohol or drug addiction. May affect performance of skilled tasks. May precipitate suicide or aggressive behaviour. Personality disorders. Hypotension occasionally occur with high dosage and parenteral admin. Elderly or debilitated patients. Pregnancy and lactation.
Adverse Reactions
Hepatotoxicity. Drowsiness and lightheadedness, sedation, muscle weakness, and ataxia. Less frequently, vertigo, headache, confusion, depression, slurred speech or dysarthria, changes in libido, tremor, visual disturbances, urinary retention or incontinence, GI disturbances, changes in salivation, and amnesia.
Drug Interactions
MAOIs. Enhanced sedation or respiratory and CV depression may occur if given with other drugs that have CNS depressant properties. Others: Fenoprofen, methadone, pethidine and opioid analgesics; disopyramide, lidocaine and quinidine; chloramphenicol, doxycycline; warfarin and coumarin; antidepressants eg, bupropion, fluoxetine, lithium and mianserin; valproate and progabide; vigabatrin, oxcarbazepine, carbamazepine, clonazepam, ethosuximide, lamotrigine, tiagabine and zonisamide, griseofulvin; teniposide; metronidazole; chlorpromazine; HIV-protease inhibitors; β-blockers; calcium-channel blockers e.g. nifedipine and verapamil; digitoxin; ciclosporin; corticosteroids; furosemide; montelukast; oral contraceptives; theophylline; levothyroxine; influenza vaccination and vitamins. Alcohol.
ATC Classification
N05BA21 - clotiazepam ; Belongs to the class of benzodiazepine derivatives anxiolytics. Used in the management of anxiety, agitation or tension.
Disclaimer: This information is independently developed by CIMS based on clotiazepam from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in